8-K: Vivani Medical and Okava Pharmaceuticals Expand Collaboration to Develop Long-Acting GLP-1 Therapy for Dogs

Vivani Medical and Okava Pharmaceuticals are expanding their collaboration to develop OKV-119, a long-acting GLP-1 therapy, for weight management, diabetes, and other cardiometabolic conditions in dogs.

Summary

• Vivani Medical and Okava Pharmaceuticals are expanding their collaboration to include dogs in the development of OKV-119, a long-acting GLP-1 therapy.
• The collaboration, initially focused on cats since 2019, now aims to address the issue of overweight and obese dogs in the United States, where over half the dog population faces this problem.
• OKV-119 leverages Vivani's NanoPortal technology for steady delivery of GLP-1 receptor agonists over extended periods.
• Okava believes that dosing every six months or longer supports a 'One-and-Done' approach, similar to Vivani's NPM-115 for humans.
• The goal is to mimic the effects of caloric restriction, improving insulin sensitivity, reducing fat mass, and enhancing energy metabolism in dogs.
• The financial terms of the expanded agreement were not disclosed.
• Vivani's lead programs, NPM-139 (semaglutide implant) and NPM-115 (exenatide implant), are miniature, subdermal GLP-1 implants under development for chronic weight management in obese or overweight individuals designed for once or twice-yearly administration.
• Vivanis emerging pipeline also includes NPM-119, which refers to the Companys six-month, subdermal, GLP-1 (exenatide implant) under development for the treatment of type 2 diabetes.

Sentiment

Score: 7

Explanation: The announcement is positive, highlighting a strategic collaboration and expansion into a new market. The potential benefits for dogs and the minimization of risks for Vivani contribute to a favorable outlook.

Positives

• The collaboration expands the application of Vivani's NanoPortal technology to a new market segment (veterinary medicine).
• The partnership minimizes costs and risks for Vivani while integrating upside potential for Vivani shareholders through future milestone payments and royalties.
• OKV-119 has the potential to improve the quality of life and extend the lifespan of dogs.
• The 'One-and-Done' approach could improve medication adherence and convenience.

Risks

• The development and commercialization of OKV-119 may face regulatory hurdles and delays.
• Clinical trials may not yield the desired results.
• The financial terms of the expanded agreement were not disclosed, making it difficult to assess the potential financial impact on Vivani.

Future Outlook

The collaboration aims to broaden the reach of Vivani's technology and capture future value within the veterinary medicine industry, which is experiencing continued growth.

Management Comments

• Okava CEO Michael Klotsman stated that OKV-119 mimics the physiological effects of fasting, improving metabolic health in dogs without significant changes in feeding routines.
• Vivani CEO Adam Mendelsohn stated that the collaboration aligns with Vivani's mission to develop innovative medicines for chronic diseases and reflects confidence in NanoPortal technology.

Industry Context

The announcement highlights the growing interest in addressing metabolic health issues in pets, mirroring trends in human healthcare. The focus on long-acting therapies aligns with the industry's push for improved medication adherence and patient convenience.

Comparison to Industry Standards

• The development of OKV-119 for dogs mirrors the development of GLP-1 therapies for humans, such as Ozempic and Wegovy, which have seen significant success in the weight management market.
• Vivani's NanoPortal technology aims to provide a competitive advantage by offering ultra-long-acting drug delivery, potentially improving patient adherence compared to daily or weekly injections.
• Other companies in the veterinary pharmaceutical space, such as Zoetis and Elanco, are also investing in innovative therapies for pets, indicating a growing market opportunity.

Stakeholder Impact

• Shareholders may benefit from the potential future value creation through milestone payments and royalties.
• Veterinarians may have a new tool to address the growing problem of obesity and metabolic decline in dogs.
• Dog owners may have a convenient and effective way to improve their pets' health and lifespan.
• Employees of Vivani and Okava may benefit from the growth and success of the collaboration.

Key Dates

Keywords

OKV-119, GLP-1 therapy, NanoPortal technology, weight management, diabetes, cardiometabolic conditions, dogs, Vivani Medical, Okava Pharmaceuticals, collaboration